The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2022 | Current and future treatment approaches for HR-MDS
In this video, Pramila Krishnamurthy, MD, King’s College Hospital NHS Foundation Trust, London, UK, discusses the treatment of high-risk myelodysplastic syndromes (HR-MDS), drawing focus on the promise of novel agents. Dr Krishnamurthy first discusses the efficacy of combining venetoclax with azacitidine, which has shown great promise for the treatment of HR-MDS. Following this, Dr Krishnamurthy explains how novel immune therapies, such as the combination of magrolimab and azacitidine, are allowing patients with poor-risk mutational profiles to get to transplant, which is the ultimate goal of HR-MDS therapy. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Ad board- Jazz
Honorarium- Astellas, Jazz
